Syndax Pharmaceuticals
Nasdaq SNDX · New York, NY
Works in Dermatology · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
Syndax Pharmaceuticals is a clinical trial sponsor based in New York, NY, listed as Nasdaq SNDX. It has 5 active clinical trials with 1,452 planned participants, across 10 therapeutic areas. Since 2021 it has completed 14 trials and stopped 4 early.
Trial track record · since 2021
Financials · Nasdaq SNDX
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Syndax Pharmaceuticals
Syndax Pharmaceuticals is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 1,452 planned participants, in Dermatology, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 14 trials and stopped 4 early.
Syndax Pharmaceuticals is based in New York, NY and is listed as Nasdaq SNDX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Syndax Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-09.
Approve Suite is not affiliated with Syndax Pharmaceuticals. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.